Logo

Gilead Sciences and Second Genome Signs a Four-Year Collaboration to Identify Biomarkers and Therapies Targeting Inflammatory Bowel Disease

Share this

Gilead Sciences and Second Genome Signs a Four-Year Collaboration to Identify Biomarkers and Therapies Targeting Inflammatory Bowel Disease

Shots:

  • Second Genome will receive $38M as upfront- up to $300M milestones for each of five target discovery programs and royalties for approved therapies. Additionally- it will receive milestones for each validated biomarker delivered under the collaboration
  • The collaboration will deploy Second Genome’s Microbiome Analytics Platform to identify biomarkers associated with clinical response in up to 5 of Gilead’s pipeline compounds in inflammation- fibrosis and other diseases and to identify up to 5 novel therapies targeting IBD over the next 4yrs.- with an option to extend the collaboration for an additional 2yrs.
  • Gilead to get the global option rights for up to 5 programs targeting all diseases along with exclusive rights to all biomarkers developed under the collaboration

Click here ­to­ read full press release/ article 

Ref: Gilead | Image:Gilead


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions